

November 12, 2022

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: 506690

Scrip Code: 506690

Dear Sir/Madam

Sub.: Financial Results for Second quarter and Six months ended September 30, 2002 published in newspapers on November 12, 2022.

Pursuant to Regulation 47 of the Listing Regulations, please find attached copies of the Financial Results for the second quarter and six months ended September 30, 2022 published in the following newspapers on November 12, 2022.

- 1. Mumbai edition of Business Standard
- 2. Mumbai edition of Sakal

This is for your information and record.

Thanking you,

For UNICHEM LABORATORIES LIMITED

PRADEEP BHANDARI Head- Legal & Company Secretary






MORGANITE CRUCIBLE (INDIA) LIMITED

Apollo Hospitals Enterprise Limited Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu Tel. +91-44-28290956 Website : www.apollohospitals.com Email: investor.relations@apollohospitals.com,



Notes:

1. The consolidated financial information of Apollo Hospitals Enterprise Limited ("the Company") for the three and six months ended September 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on November 9, 2022 and Novembe 10, 2022 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three and six months ended September 30, 2022. These consolidated financial results have been extracted from the consolidated financial information

2. Unaudited financial results of Apollo Hospitals Enterprise Limited (standalone information)

Particulars	Three months ended 30/09/2022	Preceeding Three months ended 30/06/2022	Corresponding Three months ended 30/09/2021	Year to date figures for current period ended 30/09/2022	Year to date figures for previous period ended 30/09/2021	Previous year ended 31/03/2022
Continuing Operations	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from Operations	171558	152969	165608	324527	313880	609833
Profit Before Tax	34559	25012	25143	59571	41788	85213
Profit after tax for the period	27919	33314	16143	61233	26829	57234
Discontinued Operations Revenue from Operations			116712		267912	513139
Profit Before Tax			3760		10398	14248
Profit after tax for the period			2446		6764	9269
Profit after tax for the period from continuing and discontinued operations	27919	33314	18589	61233	33593	66503
Total Comprehensive Income for the period [comprising Profit/ (Loss) for the period (after tax) & Other Comprehensive Income (after tax)]	27315	33656	18081	60971	33125	66279

3. The above is an extract of the detailed format of financial results for the three and six months ended September 30, 2022 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www. nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com

4. The Company has exercised the option of lower tax permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ('the Amendment Act"). Accordingly, the Company has recognised provision for income tax for the quarter and six months ended September 30, 2022 basis the rate provided in the said Amendment Act. The Company has re-measured the opening balance of Deferred Tax Liability (net) as at April 1, 2022 and accounted tax credit of Rs. 14,659 lakhs relating to the same in the previous guarter

5. The Company had received approval from the Regional Director, Ministry of Corporate Affairs on June 28, 2021 for the Scheme of Amalgamation with the following wholly owned subsidiary companies, with the Appointed Date being April 1, 2020:

a Apollo Home Healthcare (India) Limited and b. Western Hospitals Corporation Private Limited

Consequent to giving effect to the said Scheme of Amalgamation, the Company had created a provision against loan of Rs. 674 lakhs extended by

	Quarter &			-			(Amt INR in La
Sr.	Particular		uarter Ende		Half Yea		Year Ende
No.	Farticular	30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)	30.09.2021 (Unaudited)	31.03.2022 (Audited)
1	Total Income from operation	3,907.77	4,141.93	3,692.26	8,049.70	7,175.40	18,131.5
2	Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	520.02	589.92	701.57	1,109.94	1,312.69	5,138.0
3	Net Profit for the period before tax (after Exceptional and / or Extraordinary Items)	520.02	589.92	701.57	1,109.94	1,622.69	5,448.0
4	Net Profit for the period after tax (after Exceptional and / or Extraordinary items)	390.75	432.89	525.86	823.64	1,198.91	4,339.3
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	386.80	447.32	526.97	834.11	1,195.93	4,362.7
6	Equity Share Capital	280.00	280.00	280.00	280.00	280.00	280.0
7	Other Equity (Reserves excluding revaluation reserves)	-	-	-	-	-	11,975.4
8	Earnings Per Share (of Rs. 5/- each) (for continuing operations) Basic & Diluted	6.98	7.73	9.39	14.71	21.41	77.4

the Audit Committee and taken on record by the Board of Directors at their meeting held on 10 November 2022. The results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 -Interim financial reporting prescribed under section 133 of the companies act, 2013, read with relevant rules issues thereunder as amended from time to time.

- 2. The Statutory Auditors of the Company have conducted review of quarterly and half year ended financial results of the Company for the quarter and half year ended 30 September 2022.
- 3. The Board of Directors at its meeting held on Thursday, 10 November 2022 have declared an Interim Dividend of ₹ 9.00 per equity share. The total interim dividend amounts to ₹ 504 lakh and will be paid to the equity shareholders of the Company whose names appear in the Register of Members of the Company or in the records of the Depositories as beneficial owners of the said shares as on Wednesday, 23 November 2022 being the Record Date fixed for the purpose.
- The Financial Results have been made available to the Stock Exchange where the Company's securities are listed 4 and are posted on the Company's website (www.morganmms.com).

	For Morganite Crucible (India) Limited
	Sd/-
	Aniruddha Karve
Place: Aurangabad, India	(Director)
Date: 10.11.2022	DIN: 07180005

					•		
			62PLC012				100 10
łeg	istered Office: Unichem Bhavan, Prabhat	,		, 0	•		- 400 10
	Website: <u>www.unichemlabs.</u>			res@unich	emlabs.col	<u>m;</u>	
		.: (022) 66					
EX	FRACT OF UNAUDITED STANDALONE FINA			R THE QUA	RTER AND	HALF YEA	AR ENDED
	30'*	SEPTEME	BER, 2022				(3 1-1-1-
		Quarter	Overster	Quarter	Six months	Six months	(₹ lakhs Year
• •		ended	Quarter ended	ended	ended	ended	ended
Sr. No.	Particulars	30th Sep'22	30 th Jun'22	30 th Sep'21	30 th Sep'22	30 th Sep'21	31 st Mar'22
		(Unaudited)	<u>` </u>	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	26,563.83	24,478.13	21,696.73	51,041.96	41,777.04	94,292.6
2	Net Profit / (Loss) for the period						
	(before tax and exceptional items)	(4,982.93)	(2,327.91)	(2,658.98)	(7,310.84)	(6,297.28)	(8,674.77
3	Net Profit / (Loss) for the period before tax						
	(after exceptional items)	(5,485.17)	(2,327.91)	(2,658.98)	(7,813.08)	(6,297.28)	(8,674.77
4	Net Profit / (Loss) for the period after tax						
	(after exceptional items)	(7,546.39)	(2,327.91)	(2,143.32)	(9,874.30)	(4,926.18)	(5,542.96
5	Total comprehensive income for the period						
	[comprising of profit / loss) for the period (after tax)						
	and other comprehensive income (after tax)]	(3,916.45)	(2,121.75)	(2,361.98)	(6,038.20)	(5,168.44)	(5.76
6	Paid-up Equity Share Capital	1,408.12	1,408.12	1,408.12	1,408.12	1,408.12	1,408.1
7	Other Equity [Reserves excluding Revaluation						
_	Reserve]						2,65,795.9
8	Earnings per equity share						
	(Face value of ₹ 2/- per share) (not annualized)	(10.70)	(0.04)	(2.2.1)	(1100)	(7.00)	(= 0=
	(a) Basic	(10.72)	(3.31)	(3.04)	(14.02)	(7.00)	(7.87
	(b) Diluted	(10.72)	(3.31)	(3.04)	(14.02)	(7.00)	(7.87
	EXTRACT OF UNAUDITED CONSOLIDATED				QUARTER	AND HAL	F YEAR
	ENDED	30 [™] SEPT	EMBER, 2	022			(Filelike
		Quarter	Quarter	Quarter	Six months	Six months	(₹ lakhs Year
Sr.	-	ended	ended	ended	ended	ended	ended
No.	Particulars	30th Sep'22	30 th Jun'22	30th Sep'21	30th Sep'22	30 th Sep'21	31 st Mar'22
		(Unaudited)	`, ,	(Unaudited)	(Unaudited)	·	(Audited)
1 2	Total income from operations	32,881.93	30,960.83	29,066.08	63,842.76	58,857.34	1,26,983.2
2	Net Profit / (Loss) for the period	(4 000 05)	(0.067.46)	(1 551 00)	(6 000 51)	(0.455.04)	2,196.8
3	(before tax and exceptional items) Net Profit / (Loss) for the period before tax	(4,223.05)	(2,067.46)	(1,551.20)	(6,290.51)	(2,455.34)	2,190.8
3	(after exceptional items)	(4,725.29)	(2,067.46)	(1,551.20)	(6,792.75)	(2,455.34)	2,196.8
4	Net Profit / (Loss) for the period after tax	(4,723.29)	(2,007.40)	(1,001.20)	(0,192.13)	(2,400.04)	2,190.8
4	(after exceptional items)	(7,066.63)	(2,336.87)	(1,281.68)	(9,403.50)	(2,430.56)	3,306.1
5	Total comprehensive income for the period	(7,000.03)	(2,000.07)	(1,201.00)	(0,-00.00)	(2,-30.30)	0,000.1
5	[comprising of profit / (loss) for the period (after tax)						
	and other comprehensive income (after tax)	(2,933.98)	(1,651.47)	(1,552.37)	(4,585.45)	(2,716.76)	8,681.2
6	Paid-up Equity Share Capital	1,408.12	1,408.12	1,408.12	1,408.12	1,408.12	1,408.1
7	Other Equity [Reserves excluding Revaluation	1,-100.12	1,-100.12	1,400.12	1,-100.12	1,-100.12	1,00.1
	Reserve]						2,60,432.9



MMorgan

- Western Hospitals Corporation Private Limited to its subsidiary Apollo Lavasa Health Corporation Limited. This provision was disclosed under Exceptional Items in the standalone financial results for the year to date September 30, 2021 and year ended March 31, 2022
- 6. The Company in the year ended Mar 31, 2022 reorganised its pharmacy distribution by transferring to Apollo Healthco Limited, a wholly owned subsidiary of the Company
- 7. Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999.99 lakhs.

The utilisation of the QIP Issue proceeds upto September 30, 2022 is as follows:

Particulars	Amount in Rs. Lakhs
Fees paid to Lead Managers	1,785.00
Foreclosure of debts	25,138.00
Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited	41,000.00
Acquisition of equity stake in Apollo Hospitals North Limited	27,500.00
Loan given to Apollo Hospitals North Limited	21,576.00

8. The Company has executed definitive agreements on 5th October 2022 in connection with the acquisition of a 60% equity stake in Kerala First Health Services Private Limited ("KFHSL"), which offers quality systems driven Ayurveda medical care services under the "AyurVAID Hospitals" brand through a combination of primary and secondary equity investment with the overall transaction consideration of Rs. 2,640 lakhs.

The primary investment will be used to upgrade existing centres, set up new centres, strengthen enterprise platforms, and for digital health initiatives. Consequent to this acquisition, KFHSL would become a subsidiary of the Company

- 9. The Company had invested an amount of Rs. 27,500 lakhs in the equity capital of Apollo Hospitals North Limited (wholly owned subsidiary company) and also provided an unsecured loan amount of Rs. 21,576 lakhs for its expansion activities.
- 10. Apollo Hospitals North Limited, wholly owned subsidiary of the Company has completed the acquisition of the assets forming part of a 650 bedded potential hospital facility, which was being set up by Nayati Healthcare and Research NCR Private Limited in Gurgaon for a consideration of about Rs 47,587 lakhs (incl Stamp Duty & other incidental charges)
- 11. The Company completed the acquisition of an additional 50% stake held by Gleneagles Development Pte Limited (erstwhile joint venturer) in Apollo Multi Specialty Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), Kolkata on April 22, 2021 for a consideration of Rs. 41,000 lakhs. Consequently, AMSHL became a wholly owned subsidiary of the Company and has been consolidated effective from April 22, 2021. The resultant goodwill of Rs. 53,714 lakhs has been presented within the Healthcare segment.

The acquisition date fair value of the existing equity interest in AMSHL compared to its carrying amount resulted in a gain of Rs. 29,411 lakhs, which has been included under exceptional items

12. On November 12, 2021, Assam Hospitals Limited, a subsidiary company of the Group had acquired 64.42% shareholding in Asclepius Hospitals & Healthcare Private Limited

Based on the information available at March 31,2022, the Subsidiary Company determined a preliminary purchase price allocation based on the provisional amounts of the identifiable assets acquired and liabilities assumed, resulting in a provisional goodwill of Rs. 1,153 lakhs as at March 31, 2022, subject to finalisation of the purchase accounting. As at September 30, 2022 on receipt of complete information the purchase accounting is finalised, resulting in increase in the goodwill balance to Rs. 2,795 lakhs

13. The Honourable High Court of Karnataka on October 8, 2021 had set aside the order of the State of Karnataka, Revenue Department ("Revenue Department") initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company alleging non-compliance of certain conditions associated with the allotment of land to the said subsidiary company and have remitted it back to the Revenue Department for reconsideration and disposal. The Revenue Department had issued a show cause notice dated 9 February 2022 seeking explanations as to why the original order needs to be withdrawn for which the subsidiary company had filed a detailed response explaining there were no violations of the conditions relating to the allotment of the land. Based on legal opinion received, the subsidiary company has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in their favour

14. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

Place : Chennai Date : 10th November, 2022 for APOLLO HOSPITALS ENTERPRISE LIMITED **DR. PRATHAP C REDDY Executive Chairman**

(b) Diluted (10.04)(3.32) (1.82)Notes: The standalone financial results for the quarter and half year ended 30th September, 2022 and consolidated financial results

(Face value of ₹ 2/- per share) (not annualized)

Earnings per equity share

(a) Basic

for the quarter and half year ended 30th September 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2022. The statutory auditors have carried out a limited review of the standalone and consolidated financial results. The above is an extract of the detailed format of the unaudited standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated unaudited financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.

(10.04)

(3.32)

(1.82)

(13.36)

(13.36)

(3.45)

(3.45)

4.70

4.68

SD/

The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below

						(₹ lakns)
	Quarter	Quarter	Quarter	Six months	Six months	Year
	ended	ended	ended	ended	ended	ended
Particulars	30 th Sep'22	30 th Jun'22	30 th Sep'21	30 th Sep'22	30 th Sep'21	31 st Mar'22
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total R&D expenditure	2,957.07	2,205.28	2,520.04	5,162.35	5,617.74	11,274.10

By Order of the Board For Unichem Laboratories Limited

Dr. Prakash A. Modv Chairman & Managing Directo DIN: 00001285

Place: Mumbai Date: 11th November, 2022









& सकाळ

सॅनफ्रान्सिस्को, ता. ११ (वृत्तसंस्था)

ः आगामी दिवस कठीण असल्यामुळे

कर्मचाऱ्यांनी घरातून काम करण्याची चैन

बंद करून कार्यालयात कामाला यावे आणि

आठवड्याचे ८० तास काम करावे, असा इशारा ट्विटरचे नवे सर्वेसर्वा एलॉन मस्क यांनी

बुधवारी (ता.१०) कर्मचाऱ्यांच्या पहिल्या

कंपनीच्या येथील मुख्यालयात घेतलेल्या बैठकीत त्यांनी अनेक कठोर

निर्णयांचे सूतोवाच केले. मस्क यांनी आधी

कर्मचाऱ्यांना ई-मेल पाठवून कार्यालयात

४० तास काम करण्याचे आवाहन केले होते

व पुढील दिवस कठीण असल्याचा इशारा

बैठकीत दिला.

करण्यास बजावले.

TATA AIG

+

KK

CCMM

संमिश्र

राजीव यांच्या मारेकऱ्यांची मुक्तता ८० तास काम करा 🛇 पान १ वरून

हल्लेखोराने हत्या केली होती. निवडणूक सभेवेळी लिबरेशन टायगर ऑफ तमिल इलमची (एलटीटीई) महिला दहशतवादी धनू (तेनमोजी राजरत्नम) हिने राजीव गांधींना फुलांचा हार घातल्यानंतर त्यांच्या पायाला स्पर्श केला आणि खाली

वाकून कमरेला बांधलेल्या स्फोटकांचा स्फोट केला. हा स्फोट एवढा जोरदार होता की अनेकांचे तुकडे झाले. राजीव गांधी आणि हल्लेखोर धनू यांच्यासह १६ जणांचा जागीच मृत्यू झाला, तर ४५ जण गंभीर जखमी झाले होते. राजीव यांनी त्यांच्या कार्यकाळात श्रीलंकेत शांतिसेना पाठवली होती. या शांतिसेनाला लिबरेशन टायगर्स ऑफ तमिळ इलम या तमिळ बंडखोरांचा विरोध होता. त्यातूनच हा आत्मघातकी हल्ला घडवून आणला

होता. या प्रकरणी नलिनी, रामचंद्रन, संथान, मुरुगन, पेरारीवलन, रॉबर्ट पायस आणि जयकुमार या दोषींना जन्मटेपेची शिक्षा ठोठावण्यात आली

दिला होता. या इशाऱ्याचा या बैठकीत त्यांनी घरून काम करण्याची कर्मचाऱ्यांना मिळणारी आहे. यापुढे आपल्याला अत्यंत कठोरपणे पुनरुचार केला व कर्मचाऱ्यांना ८० तास काम सोय बंद करण्याचेही त्यांनी समर्थन केले. मेहनत करावी लागणार आहे, तुम्ही ते करू यासंदर्भातील कर्मचाऱ्यांचा प्रश्नाला उत्तर शकत नसाल तर तुम्हाला द्विटरमध्ये काहीही कर्मचाऱ्यांना अन्य सवलतीदेखील फार देताना मस्क चांगलेच भडकले होते, असे स्थान राहणार नाही, असेही मस्क यांनी स्पष्ट कमी मिळतील, असेही त्यांनी सुनावले. काही कर्मचाऱ्यांनी ट्विट करून सांगितले केले आहे.

+ एलॉन मस्क यांचा कर्मचाऱ्यांना सल्ला

• •	1		2	\sim
मबइत	पोटच्या	मलाला	आइन	विकल
3.1.		3		

मुंबई, ता. ११ : एक दिवसाच्या रात्री बेड्या ठोकल्या. पोलिसांनी मुलीला विकण्याचा डाव उधळन दिलेल्या माहितीनुसार, मुलाची खरेदी लावत पोलिसांनी बाळाची सखरूप करणारी महिला ही पेशाने नर्स आहे: सुटका केली आहे. या प्रकरणी तर मुलाची विक्री करणारी संशयित बाळाची खरेदी करणाऱ्या नर्ससह आरोपी आई असून ती बेरोजगार आहे. पोलिसांनी आईला गुरुवारी (ता. ११)

> टाटा एआयजी जनरल इन्शुरन्स कंपनी लिमिटेड नोंदणीकृत कार्यालय : पेनिन्सुला बिझनेस पार्क, टॉवर ए, १५ वा मजला, गणपतराव कदम मार्ग, लोअर परेल, मुंबई - ४० ००१३ दूर. : ०२२ - ६६६९९७६१ / फॅक्स : ०२२ - ६६५४६४६४

> ई - मेल : secretarialdepartment.tataaig@tataaig.com वेबसाइट : www.tataaig.com सीआयएन : U85110MH2000PLC128425

> > सूचना

याद्वारे सूचना देण्यात येत आहे की, कंपनीद्वारे जारी व दि. १९ डिसेंबर, २०२९ रोजी विमोचनयोग्य असलेल्या दि. १९ डिसेंबर, २०२२ रोजीनुसार अप्रतिभूत, दुय्यम, सूचिबद्ध, विमोचनयोग्य, बिगरपरीवर्तनीय पूर्णतः प्रदानित डिबेंचर्सवर देय ८.८५ टक्के (८.८५%) दराने वार्षिक व्याज प्राप्त करण्यासाठी पात्र असलेल्या कंपनीच्या

कर्जरोखे डिबेंचरधारकांच्या पात्रतेच्या निश्चितीसाठी शनिवार, दि. ४ डिसेंबर, २०२२ ही तारीख नोंद दिनांक म्हणून निश्चित करण्यात आली आहे.

कर्जरोखेधारकांनी कृपया कंपनीचे रजिस्ट्रार व ट्रान्सफर एजंट, एनएसडीएल डेटाबेस मॅनेजमेंट लिमिटेड यांना,

जयंत ॲग्रो-ऑरगॅनिक्स लिमिटेड लोगो लाइस Leadership through Innovation CIN: L24100MH1992PLC066691 नोंदणीकृत कार्यालय : ७०१, टॉवर "ए", पेनिन्शुल बिझनेस पार्क, सेनापती बापट मार्ग, लोअर परेल (पश्चिम), मुंबई ४०००१३. ईमेल : investors@jayantagro.com, वेवसाईट: www.jayantagro.com फोन : 022-4027 1300, फॅक्स: 022-4027 1399 ३० सप्टेंबर, २०२२ रोजी संपलेल्या तिमाही आणि अर्ध्या वर्षासाठी अलेखापरिक्षित एकत्रित आर्थिक परिणामांचा उतारा रलाखांमध्ये संपलेले अर्ध वर्ष संपलेली तिमाही तपशील संपलेली तिमाही 30.09.2022 30.09.2022 30.09.2029 £8,42£.28 9,58,022.00 E8,924.04 कामकाजापासून एकूण उत्पन्न कालावधीसाठी निव्वळ नफा/(तोटा) (कर पूर्व 9,002.30 8,822.38 3,024.00 अपवादात्मक आणि/किंवा असाधारण वस्तू करापूर्वीच्या कालावधीसाठी निव्वळ नफा/ (तोटा) 9,002.30 8,822.38 3,024.00 (अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) ४. कर पश्चात कालावधीसाठी निव्वळ नफा/(तोटा) 3,288.82 9,223.39 2,296.48 (अपवादात्मक आणि/किंवा असाधारण आयटम्स पश्चात) कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या_कालावधीसाठी समावेशक नफा / (तोटा) (कर पश्चात) 2,848.68 २,२८६.५५ 9,804.39 आणि इतर सर्वसमावेशक उत्पन्न (कर पश्चात)

 इक्विटी शेअर कॅपिटल (समभाग भांडवल) 9,400.00 9,400.00 9,400.00 ७. रिझव्हर्स अर्थात राखीव (मागील वर्षाच्या ताळेबंदात दाखवल्याप्रमाणे पुनर्मूल्योंकन राखीव वगळून)* ८. प्रति शेअर कमाई दर्शनी मूल्य (फेस व्हॅल्यू) रु. ५/- प्रत्येकी) बेसिक आणि डायल्युटेड 90.33 10.08 3.62 *39 मार्च २०२२ रोजी संपलेल्या वर्षांचे रिझर्व्ह रु. ४५, १३६.९० लाख होते. ३० सप्टेंबर, २०२२ रोजी संपलेल्या तिमाही आणि अर्ध्या वर्षासाठीच्या अलेखापरिक्षित एकत्रित आर्थिक परिणामांचा उतारा (रलाखांमध्ये) संग्रेकेकी ०२१ .२१

ज. क्र.	तपशाल	तिमाही	वर्ष	तिमाही
		30.09.2022	30.09.2022	30.09.2020
۹.	कामकाजापासून एकूण उत्पन्न	30,880.88	£4,408.90	20,283.29
2.	कर पूर्व नफा/(तोटा)	9,280.34	3,324.44	2,483.30
З.	कर पश्चात नफा/ (तोटा)	800.98	2,823.90	9,८६६.२८
8.	कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा/(तोटा)(करपश्चात) आणि इतर सर्वसमावेशक उत्पन्न (करपश्चात)]	१,००६.७३	२,३३७.८२	१,९५४. ४९

9. वरील उतारा हा सेबी अर्थात SEBI (सूचीबद्ध दायित्वे आणि प्रकटीकरण आवश्यकता) नियमावली, २०१५ च्या नियमन ३३

सोनियांनी नलिनीला केले होते माफ

होती. घटनेच्या कलम १४२ मधील विशेषाधिकाराचा वापर येथे धनू नावाच्या महिला आत्मघातकी करत सर्वोच्च न्यायालयाने पेरारीवलनची सुमारे ३० वर्षांनंतर सुटका करण्याचे आदेश यावर्षी २१ मे रोजी दिले होते.

राजीव गांधी यांच्या हत्येप्रकरणी नलिनीला अटक झाली तेव्हा ती गर्भवती होती. तिला गरोदर होऊन दोन महिने झाले होते. त्यानंतर सोनिया गांधींनी नलिनीला माफ केले. नलिनीच्या चुकीची शिक्षा अद्याप जगात न आलेल्या एका निष्पाप बाळाला कशी दिली जाऊ शकते, असे त्या म्हणाल्या होत्या.

मुंबई, शनिवार,

१२ नोव्हेंबर २०२२

११



CIN:L999999MH1962PLC012451 Registered Office: Unichem Bhavan, Prabhat Estate, Off S. V. Road, Jogeshwari (West), Mumbai - 400 102 Website: www.unichemlabs.com; E-mail Id.: shares@unichemlabs.com; Tel.: (022) 6688 8333

EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED

Sr.	Particulars	Quarter ended 30 th Sep'22	Quarter ended 30 th Jun'22	Quarter ended 30 th Sep'21	Six months ended 30 th Sep'22	Six months ended 30 th Sep'21	(₹ lakhs Year ended 31* Mar'22
No.		(Unaudited)	(Unaudited)		(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	26,563.83	24,478.13	21,696.73	51,041.96	41,777.04	94,292.6
2	Net Profit / (Loss) for the period						
20	(before tax and exceptional items)	(4,982.93)	(2.327.91)	(2,658.98)	(7.310.84)	(6,297,28)	(8,674.77
3	Net Profit / (Loss) for the period before tax	(.,)	(-,	(_,,	(.,,	(-,,	(0,01
-	(after exceptional items)	(5,485.17)	(2,327.91)	(2,658.98)	(7,813.08)	(6,297.28)	(8,674.7
4	Net Profit / (Loss) for the period after tax	(0,100.11)	(=,==,,	(=,====)	(.,)	(0,201120)	(0,01
1	(after exceptional items)	(7.546.39)	(2.327.91)	(2,143.32)	(9.874.30)	(4.926.18)	(5,542.9
5	Total comprehensive income for the period	(1,010.00)	(2,021.01)	(2,140.02)	(0,014.00)	(4,020.10)	(0,012.00
×	[comprising of profit / loss) for the period (after tax)						
	and other comprehensive income (after tax)]	(3,916.45)	(2,121.75)	(2,361.98)	(6,038.20)	(5,168.44)	(5.76
6	Paid-up Equity Share Capital	1.408.12	1,408.12	1.408.12	1,408.12	1,408.12	1,408.1
7	Other Equity [Reserves excluding Revaluation	1,400.12	1,400.12	1,400.12	1,400.12	1,400.12	1,400.1
6	Reservel						2,65,795.9
8							2,00,790.8
•	Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)						
	The second se	(40.70)	(0.04)	(0.04)	(11.00)	(7.00)	/70
	(a) Basic	(10.72)	(3.31)	(3.04)	(14.02)	(7.00)	(7.8
		(10					
	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED	(10.72) FINANCIA 30 [™] SEPT			(14.02) Quarter	(7.00) AND HALF	YEAR
	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED	FINANCIA 30 TH SEPT Quarter ended	L RESULTS EMBER, 2 Quarter ended	S FOR THE 022 Quarter ended	QUARTIER Six months ended	AND HALF	TEAR (₹ lakhs Year ended
Sr.	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED	FINANCIA 30 TH SEPT Quarter ended 30 th Sep'22	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22	S FOR THE 022 Quarter ended 30 th Sep'21	QUARITE: Six months ended 30 th Sep'22	AND HAL	TeAR (₹ lakhs Year ended 31* Mar'22
Sr. No.	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED Particulars	FINANCIA 30 TH SEPT Quarter ended 30 th Sep'22 (Unaudited)	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22 (Unaudited)	Guarter ended 30 th Sep'21 (Unaudited)	Six months ended 30 th Sep'22 (Unaudited)	AND HAL Six months ended 30 th Sep'21 (Unaudited)	(₹ lakhs Year ended 31* Mar'22 (Audited)
Sr. No. 1	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED Particulars Total income from operations	FINANCIA 30 TH SEPT Quarter ended 30 th Sep'22	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22	S FOR THE 022 Quarter ended 30 th Sep'21	QUARITE: Six months ended 30 th Sep'22	AND HAL	(₹ lakhs Year ended 31* Mar'22 (Audited)
Sr. No.	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED Particulars Total income from operations Net Profit / (Loss) for the period	FINANCIA 30 TH SEPT Quarter ended 30 th Sep'22 (Unaudited) 32,881.93	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83	George Contraction Contractio	CUARTER Six months ended 30 th Sep ¹ 22 (Unaudited) 63,842.76	AND HALS Six months ended 30 th Sep'21 (Unaudited) 58,857.34	▼Y=AR (₹ lakhs Year ended 31 st Mar'22 (Audited) 1,26,983.2
Sr. No. 1 2	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items)	FINANCIA 30 TH SEPT Quarter ended 30 th Sep'22 (Unaudited)	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22 (Unaudited)	Guarter ended 30 th Sep'21 (Unaudited)	Six months ended 30 th Sep'22 (Unaudited)	AND HAL Six months ended 30 th Sep'21 (Unaudited)	▼Y=AR (₹ lakhs Year ended 31 st Mar'22 (Audited) 1,26,983.2
Sr. No. 1	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ¹²² (Unaudited) 32,881.93 (4,223.05)	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46)	Cuarter ended 30° Sep'21 (Unaudited) 29,066.08 (1,551.20)	CUARTIE Six months ended <u>30^o Sep¹22</u> (Unaudited) 63,842.76 (6,290.51)	AND HALL Six months ended 30 th Sep ² 1 (Unaudited) 58,857.34 (2,455.34)	₹ YEAR (₹ lakhs Year ended 31* Mar'22 (Audited) 1,26,983.2 2,196.8
Sr. No . 1 2 3	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items)	FINANCIA 30 TH SEPT Quarter ended 30 th Sep'22 (Unaudited) 32,881.93	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83	George Contraction Contractio	CUARTIER Six months ended 30 th Sep ¹ 22 (Unaudited) 63,842.76	AND HALS Six months ended 30 th Sep'21 (Unaudited) 58,857.34	₹ YEAR (₹ lakhs Year ended 31* Mar'22 (Audited) 1,26,983.2 2,196.8
Sr. No. 1 2	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P articulars Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 2 (Unaudited) 32,881.93 (4,223.05) (4,725.29)	L RESULTS EMBER, 2 Quarter ended <u>30th Jun'22</u> (Unaudited) 30,960.83 (2,067.46) (2,067.46)	Quarter ended 30* Sep'21 (Unaudited) 29,066.08 (1,551.20) (1,551.20)	CUARTIER Six months ended 30 ⁶ Sep ²² (Unaudited) 63,842.76 (6,290.51) (6,792.75)	AND HALF Six months ended 30 ⁿ Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34)	▼Y=AR (₹ lakhs Year ended <u>31⁴ Mar²2</u> (Audited) 1,26,983.2 2,196.8 2,196.8
Sr. No . 1 2 3 4	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P articulars Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items)	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ¹ 22 (Unaudited) 32,881.93 (4,223.05)	L RESULTS EMBER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46)	Cuarter ended 30° Sep'21 (Unaudited) 29,066.08 (1,551.20)	CUARTIE Six months ended <u>30^o Sep¹22</u> (Unaudited) 63,842.76 (6,290.51)	AND HALL Six months ended 30 th Sep ² 1 (Unaudited) 58,857.34 (2,455.34)	▼Y=AR (₹ lakhs Year ended <u>31⁴ Mar²2</u> (Audited) 1,26,983.2 2,196.8 2,196.8
Sr. No . 1 2 3	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P articulars Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 2 (Unaudited) 32,881.93 (4,223.05) (4,725.29)	L RESULTS EMBER, 2 Quarter ended <u>30th Jun'22</u> (Unaudited) 30,960.83 (2,067.46) (2,067.46)	Quarter ended 30* Sep'21 (Unaudited) 29,066.08 (1,551.20) (1,551.20)	CUARTIER Six months ended 30 ⁶ Sep ²² (Unaudited) 63,842.76 (6,290.51) (6,792.75)	AND HALF Six months ended 30 ⁿ Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34)	▼YEAR (₹ lakhs Year ended <u>31⁴ Mar²2</u> (Audited) 1,26,983.2 2,196.8 2,196.8
Sr. No . 1 2 3 4	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax)]	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87)	Cuarter ended 30 ⁿ Sep ² 1 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68)	CUARTIER Six months ended 30 th Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50)	AND HALL Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,430.56)	YEAR (7 lakh: Year ended 31* Mar'2: (Audited) 1,26,983.2 2,196.8 2,196.8 3,306.1
Sr. No. 1 2 3 4 5	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax)]	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63) (2,933.98)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87) (1,651.47)	Cuarter ended 30* Sep*21 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68) (1,552.37)	(UARTIER Six months ended 30 ⁿ Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50) (4,585.45)	AND HALL Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,455.34) (2,430.56) (2,716.76)	YEAR (7 lakhs Year ended <u>31ª Mar'22</u> (Audited) 1,26,983.2 2,196.8 2,196.8 3,306.1 8,681.2
Sr. No. 1 2 3 4 5 6	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax) and other comprehensive income (after tax)] Paid-up Equity Share Capital	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87)	Cuarter ended 30 ⁿ Sep ² 1 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68)	CUARTIER Six months ended 30 th Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50)	AND HALL Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,430.56)	YEAR (7 lakhs Year ended <u>31ª Mar'22</u> (Audited) 1,26,983.2 2,196.8 2,196.8 3,306.1 8,681.2
Sr. No . 1 2 3 4 5	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax) and other comprehensive income (after tax)] Paid-up Equity Share Capital Other Equity [Reserves excluding Revaluation	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63) (2,933.98)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87) (1,651.47)	Cuarter ended 30* Sep*21 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68) (1,552.37)	(UARTIER Six months ended 30 ⁿ Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50) (4,585.45)	AND HALL Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,455.34) (2,430.56) (2,716.76)	YEAR (7 lakhs Year ended <u>31^a Mar'22</u> (Audited) 1,26,983.2 2,196.8 2,196.8 3,306.1 8,681.2 1,408.1
Sr. No. 1 2 3 4 5 6 7	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax)] and other comprehensive income (after tax)] Paid-up Equity Share Capital Other Equity [Reserves excluding Revaluation Reserve]	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63) (2,933.98)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87) (1,651.47)	Cuarter ended 30* Sep*21 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68) (1,552.37)	(UARTIER Six months ended 30 ⁿ Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50) (4,585.45)	AND HALE Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,430.56) (2,716.76)	YEAR (7 lakhs Year ended <u>31ª Mar'22</u> (Audited) 1,26,983.2 2,196.8 2,196.8 3,306.1 8,681.2 1,408.1
Sr. No. 1 2 3 4 5 6	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED Particulars Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period before tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period [comprising of profit / loss) for the period [comprising of profit / loss] for the period	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63) (2,933.98)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87) (1,651.47)	Cuarter ended 30* Sep*21 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68) (1,552.37)	(UARTIER Six months ended 30 ⁿ Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50) (4,585.45)	AND HALE Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,430.56) (2,716.76)	YEAR (7 lakhs Year ended <u>31ª Mar'22</u> (Audited) 1,26,983.2 2,196.8 2,196.8 3,306.1 8,681.2 1,408.1
Sr. No. 1 2 3 4 5 6 7	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED Particulars Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (koss) for the period (after tax) and other comprehensive income (after tax)] Paid-up Equity Share Capital Other Equity [Reserves excluding Revaluation Reserve] Earnings per equity share (Face value of ₹ 2/- per share) (not annualized)	FINANCIA 30 ^{ml} SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63) (2,933.98) 1,408.12	L RESULTS EMBER, 2 Quarter ended <u>30^{ss} Jun'22</u> (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87) (1,651.47) 1,408.12	Cuarter ended 30* Sep*21 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68) (1,552.37) 1,408.12	(UARTIER Six months ended <u>30° Sep'22</u> (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50) (4,585.45) 1,408.12	AND HALL Six months ended 30° Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,430.56) (2,716.76) 1,408.12	▼YE/AR Year ended 31* Mar'22 (Audited) 1,26,983.2 2,196.8 3,306.1 8,681.2 1,408.1 2,60,432.9
Sr. No. 1 2 3 4 5 6 7	(b) Diluted EXTRACT OF UNAUDITED CONSOLIDATED ENDED P a r t i c u l a r s Total income from operations Net Profit / (Loss) for the period (before tax and exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Net Profit / (Loss) for the period after tax (after exceptional items) Total comprehensive income for the period [comprising of profit / (loss) for the period (after tax)] and other comprehensive income (after tax)] Paid-up Equity Share Capital Other Equity [Reserves excluding Revaluation Reserve] Earnings per equity share	FINANCIA 30 TH SEPT Quarter ended 30 th Sep ⁷ 22 (Unaudited) 32,881.93 (4,223.05) (4,725.29) (7,066.63) (2,933.98)	L RESULTS EMBLER, 2 Quarter ended 30 th Jun'22 (Unaudited) 30,960.83 (2,067.46) (2,067.46) (2,336.87) (1,651.47)	Cuarter ended 30* Sep*21 (Unaudited) 29,066.08 (1,551.20) (1,551.20) (1,281.68) (1,552.37)	(UARTIER Six months ended 30 ⁿ Sep ² 22 (Unaudited) 63,842.76 (6,290.51) (6,792.75) (9,403.50) (4,585.45)	AND HALE Six months ended 30* Sep'21 (Unaudited) 58,857.34 (2,455.34) (2,455.34) (2,430.56) (2,716.76)	(₹lakhs Year

The standalone financial results for the quarter and half year ended 30° September, 2022 and consolidated financial results for the quarter and half year ended 30th September 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 11th November, 2022. The statutory auditors have carried out a limited review of the standalone and consolidated financial results. The above is an extract of the detailed format of the unaudited standalone and consolidated financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these standalone and consolidated unaudited financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com and www.nseindia.com and the Company at www.unichemlabs.com.

The aggregate amount of revenue expenditure incurred on Research and Development as included in the relevant expense heads is as tabulated below:

CONTRACTOR STOCKED AND ADDRESS STOCKED						(< lakits)
	Quarter	Quarter	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)		Six months	
Barris and a second	ended	ended	ended	ended	ended	ended
Particulars	30th Sep'22					
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)

	ागू असल्यानुसार कर्जरोखेधारकांचे संपृ नायन्ट आयडी व डीपी आयडी लागू असल रुन सर्व भविष्यकालीन पत्रव्यवहार, क ााजासंदर्भात तसेच पत्त्यातील बदलांची सूचन टाटा एआयजी जनरल इन्शुरन्स	याप्रमाणे नमूद र्जरोख्यांवरील ना द्यावी.	आणि (कांग्रेस) तिमाही आणि पुढील वेबसाईद २. लेखापरीक्षण र झालेल्या संचा	अलेखापरिक्षित आर्थिक निकालांच सहामाहीसाठी स्वतंत्र आणि एक टवर उपलब्ध आहे : www.jayar समितीने वरील निकालांच पुनरावल लक मंडळाच्या बैटकीत मान्यता दे	च्या तपशीलवार स्व त्रित अलेखापरिक्षि	राभा विशास जाह, २० सप्य २०२२ र की संगठया त आर्थिक निकालचे संपूर्ण स्वरूप गुतवणूकदारांसाठी ww.bseindia.com आणि www.nseindia.com शिफारस केली असून त्याला ११ नोव्हेंबर २०२२ रोजी जयंत ऍग्रो–ऑरगॅनिक्स लिमिटेड साठी सही/- अभय दही. उदेशी	al R&D expenditure		2,957.07	2,205.28 2,5		5 5,617.74 11,27 By Order of the B Em Laboratories Lin Dr. Prakash A. M Irman & Managing Dir
	काण : मुंबई नांक : १२.११.२०२२	सही/- आशिष शर्मा कंपनी सचिव			7'	DIN: 00355598 Date: 11*A	Movember, 2022	54 P				
	ट्ट फायझर _{CIN: L24231M}					Cor		ergy IT Park rathe Marg, F 0 / 2439 5500 ebsite: www.j	, Unit A2, 3 ^{**} Prabhadevi,) Fax : 022 bpharma.co	⁴ Floor, Unit / Mumbai 400 -2431 5331 / om E-mail : s	A, 8 [™] Floor) 025. / 2431 5334 secretarial@	jbpharma.com
	द कॅपिटल, 1802/1901, प्लॉट क्र. C-70, जी- दूरध्वनी: +91 22 6693 200 ई-मेल आयडी : contactus.india@pfi	00 फॅक्स: +91 22	2654 0274		SI.	Particulars		Quarter ende 30/06/2022		Half year		(₹ In lakhs) Year ended 31/03/2022
	३० सप्टेंबर २०२२ रोजी संपले अलेखापरिक्षित आर्थिक प				No		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	अलखापाराक्षत आायक प	।रणामाच्या वि		पतिरिक्त ₹ कोटीमध्ये)	1	Total Income from operations Net Profit for the period before tax	80,944 14,983	78,481 14,174	59,301 12,943	159,425 29,157	119,900 28,730	242,424 50,490
Î	तपशील		३० सप्टेंबर २०२२		4	Net Profit for the period after tax Total Comprehensive Income for the period after		10,520 10,570	9,789 9,060	21,628 20,510	21,695 21,300	38,604 39,005
		रोजी संपलेली तिमाही	रोजी संपलेल्या चालू वर्षासाठी	रोजी संपलेले संबंधित ३ महिने	5	Equity Share Capital Reserves	1,547	1,546	1,546	1,547	1,546	1,546 211,867
		अलेखापरिक्षित	तारीख निहाय वर्ष अलेखापरिक्षित	अलेखापरिक्षित	7	Earnings per share (EPS) (of ' 2/- each) Basic:	*14.37	*13.59	*12.65	*27.96	*28.03	49.86
-	एकूण उत्पन्न	£ £ 9.09	9202.63	<u>६५१.२</u> ९		Diluted:	*14.26	*13.56	*12.63	*27.75	*28.01	49.82
2	. तिमाही / कालावधीसाठी निव्वळ नफा (कर पूर्व, अपवादात्मक आणि/किंवा असाधारण वस्तू)	२२६.३०	୪୦६.୦၃	୩७୪.९६	No	ot Annualised tes The key performance figures of standalone una	udited financial resul	ts for the quarte	er and six mon	ths ended 30/0	09/2022 are as	: under: {₹ in lakhs;
ş	. तिमाही/ कालावधीसाठी करापूर्वी निव्वळ नफा	101.22	101.750							11-16	r ended	Year ended
8	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात)	४१५.२२	୫୳୪.ୡ୩	908.9Ę				Quarter ende	a	Hait veal		
3	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) २. तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम	૪૧५.૨૨ ૨૧૧.૦૭	४५८.६१ ३४३.६२	૧૭૪.૬૬	SI. No	Particulars	30/09/2022	Quarter ende 30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022
2	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न	३११.०७	18: \$144	0.000	No		30/09/2022 Unaudited		30/09/2021	30/09/2022	30/09/2021	Audited
	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा (कर पश्चात) आणि	399.00	३४३.६२	૧૪૨.૬५	No	Total Income from operations Net Profit for the period before tax	30/09/2022 Unaudited 73,996 13,220	30/06/2022 Unaudited 71,613 13,701	30/09/2021 Unaudited 52,673 11,766	30/09/2022 Unaudited 145,609 26,921	30/09/2021 Unaudited 107,303 27,048	Audited 218,988 47,129
1	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न	३११.०७	18: \$144	0.000	No	Total Income from operations	30/09/2022 Unaudited 73,996	30/06/2022 Unaudited 71,613	30/09/2021 Unaudited 52,673	30/09/2022 Unaudited 145,609	30/09/2021 Unaudited 107,303	Audited 218,988
5	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) . तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा (कर पश्चात)] इतिर सर्वसमावेशक उत्पन्न (कर पश्चात)] . इक्विटी शेअर कॅपिटल (समभाग भांडवल) . रिझव्हर्स अर्थात राखीव (पुनर्मूल्यांकन राखीव वगळून) मागील वर्षाच्या ताळेवंदात दाखवल्याप्रमाणे	399.00 390.C0	३४३.६२ ३४३.२३	982.94 983.90	No 1 2 3 2.	Total Income from operations Net Profit for the period before tax Net Profit for the period after tax The above financial results have been revie	30/09/2022 Unaudited 73,996 13,220 9,772	30/06/2022 Unaudited 71,613 13,701 10,129	30/09/2021 Unaudited 52,673 11,766 8,840	30/09/2022 Unaudited 145,609 26,921 19,901	30/09/2021 Unaudited 107,303 27,048 20,371	Audited 218,988 47,129 36,100
4	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा (कर पश्चात) आणि इतर सर्वसमावेशक उत्पन्न (कर पश्चात)] इक्विटी शेअर कॅपिटल (समभाग भांडवल) रिझव्हर्स अर्थात राखीव (पुनर्मूल्यांकन राखीव वगळून) मागील वर्षाच्या ताळेबंदात दाखवल्याप्रमाणे प्रति शेअर कमाई (२०/-प्रत्येकी) (वार्षिक नाही)*	३ ૧૧.૦૭ ३૧૦.૮७ ૪૪.૭५ -	રૂષ્ઠરૂ.૬૨ રૂષ્ઠરૂ.૨રૂ ષ્ઠ૪.૭૫ -	૧૪૨.૬५ ૧૪३.૧૦ ૪૪.૭५ -	No 1 2 3 2.	Total Income from operations Net Profit for the period before tax Net Profit for the period after tax The above financial results have been revie meetings held on November 11, 2022.	30/09/2022 Unaudited 73,996 13,220 9,772 wwed by the Audit C	30/06/2022 Unaudited 71,613 13,701 10,129	30/09/2021 Unaudited 52,673 11,766 8,840 d approved b	30/09/2022 Unaudited 145,609 26,921 19,901 by the Board of	30/09/2021 Unaudited 107,303 27,048 20,371	Audited 218,988 47,129 36,100 t their respective
۲. ٤	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वरसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा (कर पश्चात) आणि इतर सर्वरसमावेशक उत्पन्न (कर पश्चात)] इक्विटी शेअर कॅपिटल (समभाग भांडवल) रिझव्हर्स अर्थात राखीव (पुनर्मूल्यांकन राखीव वगळून) मागील वर्षाच्या ताळेबंदात दाखवल्याप्रमाणे प्रति शेअर कमाई (२०/-प्रत्येकी) (वार्षिक नाही)* बेसिक :	३ ११.०७ ३१०.८७ ४४.७५ - ६७.९९*	383.52 383.23 88.04 - 04.99*	૧૪૨.૬५ ૧૪३.૧૦ ૪૪.૭५ - ૨૧.૨५*	No 1 2 3 2. 3.	Total Income from operations Net Profit for the period before tax Net Profit for the period after tax The above financial results have been revie meetings held on November 11, 2022. The above is an extract of the detailed forma SEBI (Listing Obligations and Disclosure F	30/09/2022 Unaudited 73,996 13,220 9,772 ewed by the Audit C t of Quarterly Finan Requirements) Reg	30/06/2022 Unaudited 71,613 13,701 10,129 Committee and icial Results fi gulations, 201	30/09/2021 Unaudited 52,673 11,766 8,840 d approved b led with the S 5. The full fo	30/09/2022 Unaudited 145,609 26,921 19,901 by the Board of Stock Exchange ormat of the O	30/09/2021 Unaudited 107,303 27,048 20,371 of Directors at ges under Reg Quarterly Fina	Audited 218,988 47,129 36,100 t their respective gulation 33 of the ancial Results is
र ७ २	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा (कर पश्चात)] इक्विटी शेअर कॅपिटल (समभाग भांडवल) रिझव्हर्स अर्थात राखीव (पुनर्मूल्यांकन राखीव वगळून) मागील वर्षाच्या ताळेबंदात दाखवल्याप्रमाणे प्रति शेअर कमाई (२०/-प्रत्येकी) (वार्षिक नाही)* बेसिक : डायल्युटेड : प : उपरोक्त उतारा हा SEBI (सूचीबद्ध दायित्वे आणि प्र अंतर्गत स्टॉक एक्स्चेंजमध्ये दाखल केलेल्या त्रैमारि	३११.०७ ३१०.८७ ४४.७५ - ६७.९९* ६७.९९* देकटीकरण आवश्य सेक आर्थिक निकाल	३४३.६२ ३४३.२३ ४४.७५ - ७५.११* ७५.११* जंच्या तपशीलवार स	9४२.९५ 9४३.९० ४४.७५ - ३१.२५* ३१.२५* ३१.२५*	No 1 2 3 2. 3.	Total Income from operations Net Profit for the period before tax Net Profit for the period after tax The above financial results have been revie meetings held on November 11, 2022. The above is an extract of the detailed forma	30/09/2022 Unaudited 73,996 13,220 9,772 ewed by the Audit C t of Quarterly Finan Requirements) Reg	30/06/2022 Unaudited 71,613 13,701 10,129 Committee and icial Results fi gulations, 201	30/09/2021 Unaudited 52,673 11,766 8,840 d approved b led with the S 5. The full fo id www.nsei	30/09/2022 Unaudited 145,609 26,921 19,901 by the Board of Stock Exchangermat of the of india.com an	30/09/2021 Unaudited 107,303 27,048 20,371 of Directors at ges under Reg Quarterly Fina d the Comp	Audited 218,988 47,129 36,100 t their respective gulation 33 of the ancial Results is
५ ६७ ८	(अपवादात्मक आणि/किंवा असाधारण वस्तू पश्चात) तिमाही/ कालावधीसाठी कर पश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण आयटम पश्चात) तिमाही/कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न [या कालावधीसाठी समावेशक नफा (कर पश्चात)] इक्विटी शेअर कॅपिटल (समभाग भांडवल) रिझव्हर्स अर्थात राखीव (पुनर्मूल्यांकन राखीव वगळून) मागील वर्षाच्या ताळेबंदात दाखवल्याप्रमाणे प्रति शेअर कमाई (२०/-प्रत्येकी) (वार्षिक नाही)* बेसिक : डायल्युटेड : प : उपरोक्त उतारा हा SEBI (सूचीबद्ध दायित्वे आणि प्र	३११.०७ ३१०.८७ ४४.७५ - ६७.९९* ६७.९९* स्कटीकरण आवश्य सेक आर्थिक निकाल स्टॉक एक्सचेंजच्य	३४३.६२ ३४३.२३ ४४.७५ - ७५.११* ७५.११* जंच्या तपशीलवार स 1 पुढील वेबसाइट्स	98२.९५ 98३.९० ४४.७५ - ३१.२५* ३१.२५* ३१.२५* २९५ च्या नियमन ३३ वरूपाचा एक उतारा www.bseindia.	No 1 2 3 2. 3.	Total Income from operations Net Profit for the period before tax Net Profit for the period after tax The above financial results have been revie meetings held on November 11, 2022. The above is an extract of the detailed forma SEBI (Listing Obligations and Disclosure F available on the Stock Exchange websi	30/09/2022 Unaudited 73,996 13,220 9,772 ewed by the Audit C t of Quarterly Finan Requirements) Reg	30/06/2022 Unaudited 71,613 13,701 10,129 Committee and icial Results fi gulations, 201	30/09/2021 Unaudited 52,673 11,766 8,840 d approved b led with the S 5. The full fo id www.nsei	30/09/2022 Unaudited 145,609 26,921 19,901 by the Board of Stock Exchang ormat of the of india.com an	30/09/2021 Unaudited 107,303 27,048 20,371 of Directors at ges under Reg Quarterly Fina d the Comp	Audited 218,988 47,129 36,100 t their respective gulation 33 of the ancial Results is pany's website

+ COMMITYKK